Abstract:Objective:To investigate the influence factors of allograft acute rejection (AR) at the metaphase and long-term after kidney transplantation and the postoperative survival of allograft.Methods:The clinical data were retrospectively analysed in 43 recipients who accepted kidney transplantation were more than 1 years and were diagnosed with AR by allograft renal biopsy during January 2018 to December 2019. Seventeen of them with acute antibody-mediated rejection were as acute antibody rejection group, 26 of them with acute T cell-mediated rejection were as acute T cell rejection group, and 39 recipients who got kidney transplantation during the same period (in 2 weeks) were matched as control group. Paired sample t test or one-way ANOVA was used to compare the measurement data conforming to normal distribution among multiple groups. Chi-square test or Fisher exact probability was used for comparison between counting data groups. Kaplan-Meier was used for survival analysis and log-rank was used for comparison. A P<0.05 was considered statistically significant.Results:The proportion of 2 mismatches at HLA-A sites in HLA match before operation (4/17) was more higher in acute antibody rejection group than that in control group (1/39), and the difference was statistically significant (P=0.026). Serum creatinine and estimated glomerular filtration rate (eGFR) at the onset and last time of AR were higher in acute antibody rejection group and acute T cell rejection group than those before AR (all P<0.05). Serum creatinine and eGFR at the onset and last time of AR in acute antibody rejection and acute T cell rejection group were higher than those in control group (all P<0.05). The proportion of chronic kidney disease (CKD)-4 recipients in acute antibody rejection group was lower than that in acute T cell rejection group (χ2=5.73, P<0.05). The proportion of CKD-4 recipients in acute T cell rejection group and the proportion of renal allograft failure in acute antibody rejection group were higher than those in control group (χ2=17. 727 and 9.882, all P<0.05). When AR happened, the rate of PRA-Ⅰ positive recipients [41.2% (7/17)] and the rate of PRA-Ⅱ positive recipients [88.2% (15/17)] in acute antibody rejection group were both higher than those in acute T cell rejection group [11.5% (3/26) and 26.9% (7/26), respectively], the difference had statistical significance (P=0.042, P<0.001). The serum concentration of tacrolimus was significantly decreased in the acute antibody rejection group (3.72±0.76) ng/mL and in the acute T cell rejection group (3.37±0. 86) ng/mL when the AR occurred, which were all lower than that of the control group (5.73±1.25) ng/mL, the difference had statistical significance (all P<0.05), and also lower than the serum concentration of tacrolimus before AR occurred, the difference had statistical significance (t=7.120 and 6.216, all P<0.05). There were 4 recipients in the acute T cell rejection group used cyclosporine, and the serum concentration of cyclosporine of 3 recipients among them was not up to the mark at 33 (112.4 ng/mL), 36 (138.3 ng/mL) and 55 (7.0 ng/mL) months after transplantation. The serum concentration of cyclosporine of 2 recipients who used cyclosporine in the acute T cell rejection group was 43.2 (16 months after transplantation) and 24.6 ng/mL (177 months after transplantation), which were not up to the mark. All the recipients were followed up until June 30, 2021, the survival rate of transplant kidney of the acute antibody rejection group was lower than the control group (χ2=8.738, P<0.05).Conclusions:Mismatch at the HLA-A sites and the lower serum concentration of tacrolimus were the important factors for inducing AR in the metaphase and long-term after kidney transplantation. Acute antibody-mediated rejection was the important factor that affected the survival of transplant kidney.

Clinical observations on acute rejection of elderly donor kidneys in kidney transplant recipients of different ages

Clinical Study on Renal Transplantation in Aged Recipients:A Report of 126 Cases

Influencing factors and outcomes of acute rejection within one year after pediatric kidney transplantation

Clinical Presentations and Outcome Analysis of Renal Transplant in Elderly Patients——a Single Center Retrospective Study

Impact of Donor Age on Liver Transplant Outcomes in Patients with Acute-on-Chronic Liver Failure: A Cohort Study.

Clinical analysis on living related renal transplantation from donors above 60 years old

Acute rejection in hepatic allograft

A clinical study on renal transplantation: report of 46 cases

Clinical study on allograft acute rejection at metaphase and long-term after kidney transplantation

Immune Reconstitution and Survival of Patients after Allogeneic Hematopoietic Stem Cell Transplantation from Older Donors

The Effect of Donor-Recipient Body Surface Area Ratio on Donor Age and Donor Glomerular Filtration Rate in Chinese Patients Undergoing A Living-Donor Kidney Transplant

Significance of the donor age effect on kidney transplants

Pre-transplant Impact Factors of Acute Rejection after Kidney Transplantation

Elder Living Related Donor Kidney Transplantation: Clinical Analysis of 14 Cases

Pathological changes of renal grafts from elderly donor kidney in young recipients

Effect of acute humoral rejection on renal allograft survival

Impact of Acute Rejection Episodes on Long-Term Renal Allograft Survival

Kidney transplantation in the aged

Antidonor T-Cell Responses Are Not Attenuated in Elderly Kidney Transplant Recipients

Risk Factors of Kidney Re-Transplantation Recipients and Graft Survival During the Long-Term Follow-Up

[Completely Reversed Acute Rejection Episodes Do Not Influence the Long-Term Renal Allograft Survival].